

Original Research Article

The Role of PTEN Gene Deletion In Prostate Cancer In Relation To Proliferative Capability of Malignant Cells

Nabeel Tawfeeq Kammuna* Kaswr Mosa Al-Taraihi Asaad Abdullhamza Al-janabi
 Al-Diwanya Teaching Hospital, Al-Diwanya, IRAQ

*E-mail: nabeelkamwhite@yahoo.com

Accepted 28 September, 2016

Abstract

PTEN gene is a tumor suppressor gene located in 10q23,3 that encode dual- specificity protein and lipid phosphatase with tensin homologue. The PTEN protein signals adjust cell splitting up and express cells to enter normal cell death way. Deletion of PTEN leads to over-activation of AKT, which in turn, is related with unrestrained cell production. In this cross section study, we examined 50 paraffin-embedded blocks belongs to 50 patients with proved prostate cancer, All slides subjected to IHC KI67 Ab (which is a parameter of proliferative activity of malignant cells), and to 1 molecular study of PTEN gene in all tissues by using CISH technique.

The association between PTEN gene status examined by CISH technique with KI67 score performed by IHC technique , is highly significant, in that we get 71.43% (25/35) of no deletion cases had KI67 score $\leq 10\%$ of cells, while in cases with PTEN gene deletion , we had 73.33% (11/15) of cases carry KI67 score $> 10\%$ of cells.

Key words : PTEN- phosphatase and tension, Akt- Antigen Kinase Thymoma, CISH- chromogenic in situ hybridization, FISH- Fluorescent in situ hybridization.

الخلاصة

جين PTEN هو جين الكابتة للورم موجود في كروموسوم 10q23,3 ذو خاصية مزدوجة حيث يزيل الفوسفات عن البروتينات والدهون حاملا لمئات مجال tensin. بروتين PTEN يقوم بإرسال إشارة لتنظيم انقسام الخلايا ويوجه الخلايا لدخول مسار موت الخلايا الطبيعي, فقدان هذا الجين يؤدي الى تحفيز بروتين AKT وهذا بدوره يرتبط مع انقسام الخلايا غير المنضبط.

في هذه الدراسة (ذات المقطع العرضي), درسنا 50 عينة من مقاطع البارافين تنتمي إلى 50 مريضاً يعانون من سرطان البروستاتا مؤكد, كافة الشرائح تعرض للدراسة بواسطة المعلمات المناعية النسيجية مع المعلم KI67 (وهو معلم النشاط التكاثري للخلايا الخبيثة), والدراسة الجزيئية لجين PTEN في جميع الأنسجة باستخدام تقنية CISH

العلاقة بين وضع الجين PTEN المفحوص بواسطة تقنية CISH مع مؤشر KI67 المنجز بتقنية المعلمات المناعية النسيجية , أمر مهم للغاية, حيث ان 71.43% (25/35) من حالات عدم الحذف لجين PTEN قد سجلوا مؤشر $KI67 \geq 10\%$ من الخلايا, اما في حالات حذف الجين PTEN, كان لدينا 73.33% (11/15) منها تحمل درجة $KI67 < 10\%$ من الخلايا. وبالإضافة إلى ذلك وجدنا أن 100% من الحالات حذف الجينات PTEN المتماثل كانت النتيجة $KI67 < 10\%$ من الخلايا, في حين أن 63.63% فقط من الحالات حذف PTEN الجينات المتخالفة لديها $KI67 < 10\%$ من الخلايا.

Introduction

Prostatic cancer is still one of the major health problems all over the world, and is one of the leader causes of cancer death in men. It forms a significant percentage of hidden malignancies existing with secondary

metastasis. prostate cancers exhibit a uneven variety of clinical and behavioral forms, ranging from sluggish-mounting tumors of slight clinical consequence to extremely aggressive metastatic and deadly disease [1]. The PTEN gene, is a tumor suppressor gene located on chromosome

10q23,3 that encodes a dual-specificity protein and lipid phosphatase and tensin homolog, it targets the PIP3, converting it back to PIP2 has an important role in determine the aggressive behavior of prostate cancer[2].

PTEN protein signals regulates cell dissection and can also straight cells to go into a usual cell death lane. As a controller of PI3K signaling [3], defeat of PTEN leads to over-establishment of AKt, which in turn, is coupled with unrestrained cell production, reduce apoptosis, and angiogenesis [4]. Inactivation of PTEN is frequent in prostate cancer, especially the metastatic types [5].

The Ki-67 antigen was initially recognized by a German researchers in the 1980, it is a non-histone protein was [6]. researches have documented the contribution of Ki-67 in the polymerase ribosomal RNA synthesis. the protein has an vital role in cell separation, its exact role is still ambiguous [7].

Mostly, Ki-67 is calculated on paraffin blocks by an immunohistochemical technique. overall, the Ki-67 gain is distinct as the proportion of whole number of malignant cells that have nuclear staining [7]. So by using the KI-67 expression in paraffin embedded sections, enable us to predict the prostatic carcinoma prognosis through linking its level of expression with the proliferative capacity of tumor cells.

Chromogenic In Situ Hybridization

Is a molecular procedure so as to join the colored signal discovery technique of immunohistochemistry with hybridization. CISH procedure worn to sense the attendance or lack of definite area of DNA, as perform in FISH technique. though, CISH is much more practical in diagnostic laboratories because it uses bright-field microscopes rather than the more expensive and complicated fluorescence microscopes used in FISH.

CISH probes are connected with digoxigenin and can be recognized by bright-field microscope [8].

Aims of The Study

recent hard work are focusing on detecting the genes and thoughtful the pathways concerned in disease succession, its forceful performance and treatment unwilling.

PTEN is thought to be deleted in variety of tumors, particularly prostatic cancer, We hope in this study to clarify the genetic alteration of PTEN gene in patients with prostatic cancer in relation to Ki-67 which is a protein present in the nucleus and linked with ribosomal RNA combination, and the cell cycle progression (CCP) gain, to assess the proliferative capability of tumor cells.

Materials and Methods

Samples collection

In this retrospective study, we used 50 paraffin embedded prostate cancer sections from the records of branch of pathology in Al-Sader teaching hospital and the private laboratories with reference guide to the patients files from the Middle Euphrates center for oncology. tissue samples were taken from patients went to physicians to be display a variety of prostate cancer symptoms such as frequent and urgent urination, difficulty in voiding and hematuria, and their prostate will be examined by one or more of these following procedures: digital rectal examination, PSA level assay, computed tomography, and MRI. We collect 50 sample for those with total prostatectomy and the trucut biopsies that proved as prostate carcinoma, after we exclude all the specimens that lacking the clinical date, full investigations, or those with a controversy about their diagnosis. All the clinical data were collected from patient file: age, ultrasonographic reports, preoperative serum PSA.

Sectioning

Sectioning of paraffin embedded blocks done by using the Leica rotary microtome in department of pathology/Al-Kufa Collage of Medicine, using extremely fine steel blades, Paraffin sections are usually cut at a thickness 5µm ensuring that only a

single layer of cells makes up the section. Sections are now “floated out” on the surface of warm water in a flotation bath to flatten them and then picked up onto microscope slides.

Staining the slides

Before staining, the slides put in electric oven at 60°C to remove the paraffin from them, in about 30 minutes. The usual stain Hematoxylin and Eosin (H&E) is used to provide essential structural information about the specimens. After staining, the sections are covered with a glass coverslip. Interpretation of slides done by authors to grading them according to last updated Gleason score.

Immunohistochemistry

Detection (staining) system: Dako EnVision+ system-HRP (AEC) code K4004

Staining Procedure

relate Peroxidase building block, sufficient diluted primary antibody or negative control reagent to coat block, put adequate peroxidase connected Polymer, put adequate of the ready-to-use AEC+ substrate-chromogen, then put hematoxylin counterstain, then slides mounted and cover-slipped with an aqueous-based rising medium such as Glycerol Mounting Medium.

KI-67 Antibody Kit

Dilution: the dilution range of 1:100 when useful on paraffin sections. By take 20 minutes heating epitope recovery in Target Retrieval Solution, Low pH, and incubate at 20 min. with the primary antibody [9].

Evaluation of Staining Results

In evaluation of staining results for ki-67 expression we estimate the proportion of Ki-67-positive malignant cells and divide the number by the total number of malignant cells within one HPF, and were categorised into four degrees: grade 0 (< 1% of malignant cells), grade 1 (1-10% of malignant cells)

grade 2 (11-30% of malignant cells), grade 3 (> 30% of malignant cells) [10]. For statistical analysis, the KI67 score categorized into dichotomous variable ($\leq 10\%$, $> 10\%$) as used by Cuzick J et al in 2012 [13].

The Zytodot2C CISH Implantation Kit Protocol

(ZytoDot 2C SPEC PTEN/CEN 10 Probe, code-3053) Molecular study of PTEN gene in which, Dual-color CISH was carried out on tissue sections, to map the PTEN gene on chromosome 10q23.3 region, the 5 μ m tissue sections were deparaffinized, proteolyses by pepsin solution, put in Pretreatment Solution EDTA, Heat in a covered staining jar standing in a boiling water bath to 37°C, 50°C, then to at 95°C. Dehydration: in 70%, 90%, and 100% ethanol, each for 1 min.

Air dry sections, denature the slides at 50°C for 5 min. then 78-80°C for 5 min., e.g. on a hot plate. transfer the slides to a humidity chamber and hybridize overnight at 37°C (e.g. in a hybridization oven), remove the cover slips, immerse slides in 1x Wash Buffer TBS (prepared using WB5) and drain off or blot off the 1x Wash Buffer TBS. Apply Anti-DIG/DNP-Mix (AB14) dropwise (3-4 drops per slide) to the slides and incubate for 20 min. at 37°C in a humidity chamber. Then in the same manner apply HRP/AP-Polymer-Mix, AP-Red Solution, Apply HRP-Green Solution, counterstain and dehydrate the slides (modified from ZytoVision and ZytoDot of ZytoVision GmbH catalogue 2015).

Then we counted chromogenic signals in 100 non-overlapping interphase nuclei for each sample, so PTEN gene deletion was defined in tumor nuclei that contain one or no 10q23.3 locus signal.

Interpretation of CISH Results

The PTEN probe is labeled with digoxigenin (DIG), that results in permanent dark-green signals, the probe also labeled with dinitrophenyl (DNP) that results in permanent bright-red signals by using AP-Red solution. By this procedure we can detect 2 green and 2 red distinct dot-shaped signals with rounded edges in each nucleus in normal diploid cells, but in mitotic cells additional signals may be visible (ZytoDot 2C CISH Implementation Kit catalogue 2015).

Total lake of probe spots (green spots) in $\geq 60\%$ of malignant nuclei of the tissue specimens, considered as homozygous deletion of PTEN gene, with presence of one or two green signals in the remaining nuclei, while absence of one probe signal (green signal) in $\geq 60\%$ of tumor nuclei of

tissue spot, was defined as heterozygous deletion of PTEN gene. [10]

Results

The mean age of patients participating in the current study was 68.18 ± 8.72 years and their ages ranged from 48- 87 years. The division of patients according to 10 years intervals was outlined in table 1

Table 1 : Distribution of patients according to 10 years age intervals

Age interval	No. of patients	%
< 50 years	1	2.0
50-59 years	5	10.0
60-69 years	17	34.0
70-79 years	20	40.0
80-87 years	7	14.0
Total	50	100.0

The mean of total prostatic specific antigen (PSA) serum level of the study population (preoperative measure) was 31.57 ± 39.45 ng/ml and a median of 31.57 ng/ml. The

range of PSA was (0.9 up to >100 ng/ml). The patients were classified into four groups according to the serum level of PSA as follows (Table-2).

Table 2: Classification of patients according to serum PSA level

PSA	No.	%
≤ 4 nmol/ml	12	24.00
$>4 - \leq 10$ nmol/ml	14	28.00
$>10 - \leq 20$ nmol/ml	4	8.00
>20 nmol/ml	20	40.00
Total	50	100.00

According to Gleason score, patients were categorized into: 22 patients (44%) with <7 score, 8 patients (16%) with score of 7 and

the rest of patients (40%) with score of >7 (table 3). Median Gleason score was 7 and the range was 3-9.

Table 3: Classification of patients according to Gleason score


Gleason score	No.	%
<7	22	44.00
7	8	16.00
>7	20	40.00
Total	50	100.00

According to Ki67 score, 29 patients (58%) had score $\leq 10\%$ of tumor cells, while 21 patients (42%) had score $> 10\%$ of tumor cells. $\leq 10\%$ score included score 0 and score 1 and involved 16 patients

(32%) and 13 patients (26%), respectively, whereas $> 10\%$ score included score 2 and 3 and involved 14 patients (28%) and 7 patients (14%), respectively (Table4).

Table 4: Distribution of patients according to ki67 score

ki67 score		No.	%	No.	%
$\leq 10\%$ score	0	16	32.00	29	58.00
	1	13	26.00		
$>10\%$ score	2	14	28.00	21	42.00
	3	7	14.00		
Total		50	100.00	50	100.00

**Figure 1:** prostate cancer –KI67 score 0. (X400)




Figure 2: prostate cancer –KI67 score 1(X400)




Figure 3: prostate cancer-KI67 score 2.(X400)




Figure 4 :prostate cancer-KI67 score 3

According to CISH method, patients were found to have the following: deletion was present in 15 patients (30%): 4 of them showed homozygous genotype (8%) and

11 showed heterozygous genotype (22%). The rest of patients (70%) had no gene deletion (figure 5).




Figure 5: Pie chart showing the results of CISH procedure

Figure 6: prostate cancer- CISH image show no PTEN deletion (401x400) oil immersion lens






Figure 7: prostate cancer-CISH image show heterozygous deletion of PTEN gene.(480x361) oil immersion lens

Figure 8: prostatic cancer. CISH image show homozygous deletion of PTEN 9565x306) oil immersion lens.



The association between Gleason score and ki67 score is shown in table 5. Chi-square test was not valid as more than 20 % of the

cells possessed an expected count of less than 5.

Table 5: The association between Gleason score and ki67 score

Gleason								
	<7		7		>7		Total	
ki67	N	%	N	%	N	%	N	%
0	8	36.36	2	25.00	6	30.00	16	32.00
1	7	31.82	2	25.00	4	20.00	13	26.00
2	4	18.18	3	37.50	7	35.00	14	28.00
3	3	13.64	1	12.50	3	15.00	7	14.00
Total	22	100.00	8	100.00	20	100.00	50	100.00

Chi-square test is not valid because more than 20 % of the cells had expected counts of less than 5

Association between PTEN gene status in CISH with ki67 score


The association between CISH status of PTEN gene and ki67 score is shown in tables 6 and 7 and figure 9. It was proved to be highly significant ($P < 0.01$).

Table 6: Association between CISH status and ki67 score

CISH	0				ki67				Total	
	N	%	N	%	N	%	N	%		
No deletion	13	37.14	12	34.29	6	17.14	4	11.43	35	100.00
Heterozygous deletion	3	27.27	1	9.09	6	54.55	1	9.09	11	100.00
Homozygous deletion	0	0.00	0	0.00	2	50.00	2	50.00	4	100.00
Total	16	32.00	13	26.00	14	28.00	7	14.00	50	100.00

Table 7: Association between CISH status and ki67 score after rearrangement

CISH	Ki672				Total		P-value
	>10%		≤10%		N	%	
Deletion	11	73.33	4	26.67	15	100.00	0.003
No deletion	10	28.57	25	71.43	35	100.00	
Total	21	42.00	29	58.00	50	100.00	

**Figure 9:** Association between CISH status and ki67 score after rearrangement. (ki67 negative= ki67≤10%, ki67positive=ki67> 10%)

ki67 has 73.3% sensitivity and 71.4% specificity to CISH status. The Odd Ratio

is 6.8 , 95% C.I = 1.76- 26.76, Z statistic= 2.78, significant level P= 0.0054

Discussion

The age distribution of our patients reflects the association of prostate cancer with old age patients as proved by Maria Svensson et al [14], who concluded that the tumor become more common with advancing age and had the average age of his patients 70 years. Were 40% of our patients are in 70-79 years intervals, and in seldom we find patient under 50 years (1 patient).

In this study , there is high range of PSA level (0.9 - >100 ng/ml) and there is high percentage of patients 40 %(20/50) have PSA serum level > 20 ng/ml. this display the relative association between PSA level and prostate cancer, so the benefit of applying the screening program of measuring PSA serum level annually to every man aged more than 50 years is highly significant to be depended in our

country as it was agreed by FDA in U.S. [14].

In immunohistochemical study of KI67 marker to all slides, we admix score 0+1 in one category (≤10% of tumor cells), and admix score 2+3 in other category (> 10% of tumor cells), as it performed by Kazuhiro Tabata et al [10] and Cuzick et al [13] to get more advantageous analysis. So the proliferative capacity of 29 cases (58%) is low compared to high proliferative capacity of 21 cases (42%), that's reflects the relative high percent of production in prostate malignant cells, So the proliferative capacity of 29 cases (58%) is low compared to high proliferative capacity of 21 cases (42%), that's reflects the relative high percent of proliferation in prostate cancer cells.

In molecular study of PTEN gene status we used CISH technique as an alternative procedure to FISH, first because CISH is

much more practical in diagnostic laboratories since it uses bright-field microscopes rather than the more expensive and complicated fluorescence microscopes used in FISH[13]. Second reason, is that we can get a permanent images to the slides ,permits to further evaluation of them by authors.

Only a few studies have analyzed the frequency of PTEN deletion using FISH or CISH techniques , which are regarded as the gold standard for determination of gene copy numbers in tissue samples, or they used

In the previous studies PTEN deletion were reported from 17%-68% [12], Maria Svensson et al in 2015(14), they identified PTEN gene deletion in 37.4% (68/182) of cases by CISH technique, heterozygous PTEN gene deletion was seen in 19.2% (35/182), and homozygous deletion was seen in 18.1% (33/182) of cases, these results in general be in agreement with our results.

Association between PTEN gene status in CISH with KI67

The association between PTEN gene status examined by CISH technique with KI67 score performed by immunohistochemical technique, is highly significant in statistical analysis ($P=0.003$), in that we get 71.43% (25/35) of no deletion cases had KI67 score $\leq 10\%$ of cells, while in cases with PTEN gene deletion, we had 73.33% (11/15) of cases carry KI67 score $>10\%$ of cells. In addition we found that 100% of the homozygous PTEN gene deletion cases had KI67 score $>10\%$ of cells, while 63.63% of the heterozygous PTEN gene deletion cases had KI67 score $>10\%$ of cells.

So the sensitivity of KI67 scoring test to detect PTEN gene status in prostate cancer is 73.33%, with 71.43 % specificity. But this test had 100% sensitivity to detect homozygous deletion of PTEN gene. The Odd Ratio is 6.8, 95% C.I = 1.76- 26.76, Z statistic= 2.78, significant level $P=0.0054$. Krohnet al [12] found PTEN gene status and KI67 score data was significantly higher in PTEN deleted cases than undeleted cancers ($P=0.03$).

Conclusion

The KI67 score in IHC can detect in sensitive way the genomic state of PTEN gene, so we expect to have gene deletion in advanced KI67 score.

References

- 1.Meriç Tugba AKGUN, Nesrin TURACLAR and Hasibe Cingilli VURAL.A Study on PTEN Tumor Suppressor Gene Mutations in Turk Patients with prostate carcinoma.Int.J.Curr.Microbiol.App.2014; Sci 3(3): 791-803.
- 2.Gustafson S, Zbuk KM, Scacheri C, Eng C . Cowden syndrome. Semin Oncol.2007; 34:428–434.
- 3.Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgar ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV . Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet.1997; 15:356–362.
- 4.Lloyd KM II, Dennis M.Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 58:136–142 gene, PTEN, in sporadic thyroid tumors. Cancer Res.1963; 57:4710–4713.
- 5.Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, Westra WH, Zeiger MA, Jen J, Sidransky D . Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer.1998; 23:239–243.
- 6.Gerdes J, Schwab U, Lemke H, Stein H.(1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer.1983; 31:13-20
- 7.Bullwinkel J, Baron-Luhr B, Ludemann A, et al. Ki67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol.2006; 206:624-635.
8. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart M J, Isola

- J. "Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples". *The American Journal of Pathology*.2000; 157 (5): 1467–72. doi:10.1016/S0002-9440(10)64785-2. PMC 1885742. PMID 11073807
9. Key G, Kubbutat MH, Gerdes J. Assessment of cell proliferation by means of an enzyme-linked immunosorbent assay based on the detection of the Ki-67 protein. *J Immunol Methods*.1994;177:113-117.
10. Kazuhiro Tabata, Tomonori Tanaka, Tomayoshi Hayashi, Takashi Hori, Sayuri Nunomura, Suguru Yonezawa and Junya Fukuoka. Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. *BMC Clinical Pathology*.2014;14:23
11. Konishi N, Nakamura M, Kishi M, Nishimine, M, Ishida E, Shimada k. Heterogeneous methylation and deletion patterns of the INK 4a/ARF locus within prostate carcinomas. *Am J Pathol*.2002; 160:1207-1410.1016/S002-9440(10)62547-62543.
12. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S and Schlomm T. Genomic deletion of PTEN is associated with tumor progression and early PAS recurrence in ERG fusion – positive and fusion –negative prostate cancer. *Am J Pathol*.2012;181(2):401-12
13. Cuzick J, Berney DM, Fisher G, Mesher D, Moller H, Reid JE, Perry M, Park J, Younus A, Gutin A. Foster CS, Scardino P, Lanchbury JS, Stone S on behalf of the Transatlantic Prostate Group . Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. *Br J Cancer*.2012: 1095-1099.
14. Maria A Svensson, Roopika Menon, Jessica Carlsson, Wenzel Vogel, Ove Andrén, Michael Nowak and Sven Perner . Combination of Multiple Markers Predicts Prostate Cancer Outcome. *J Mol Biomark Diagn*.2015;6:213.